Dextromethorphan reduces neocortical ischemic neuronal damage in vivo

Charles P. George, Mark P. Goldberg, Dennis W. Choi, Gary K. Steinberg

Research output: Contribution to journalArticlepeer-review

122 Scopus citations


The dextrorotatory morphinan dextromethorphan (DM), a clinically tested antagonist of the N-methyl-d-aspartate (NMDA) receptor-channel complex, was tested in an in vivo model of acute transient focal cerebral ischemia. Rabbits were randomly assigned to pretreatment with a 20 mg/kg i.v. bolus followed by 10 mg/kg/h of 0.4% DM in normal saline (NS), or with an equivalent volume of NS alone. They then underwent 1 h occlusion of the left internal carotid artery and anterior cerebral artery followed by 4 h of reperfusion. DM-treated animals showed a significant decrease in the percentage of severe neocortical ischemic neuronal damage (10.5%), as compared to NS-treated animals (49.6%).

Original languageEnglish (US)
Pages (from-to)375-379
Number of pages5
JournalBrain Research
Issue number2
StatePublished - Feb 9 1988


  • Dextromethorphan
  • Ischemia
  • N-methyl-d-aspartic acid (NMDA)
  • Neocortex
  • Striatum

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology


Dive into the research topics of 'Dextromethorphan reduces neocortical ischemic neuronal damage in vivo'. Together they form a unique fingerprint.

Cite this